Evidence map›Paper›PMID 38270128›Full record

ArticleEmerging infectious diseases2024

Prevalence of SARS-CoV-2 Infection among Children and Adults in 15 US Communities, 2021

Jessica Justman, Timothy Skalland, Ayana Moore, Christopher I Amos, Mark A Marzinke, Sahar Z Zangeneh, Colleen F Kelley, Rebecca Singer, Stockton Mayer, Yael Hirsch-Moverman and 23 more

Open access · diamondAbstract read
In one paragraph

Article in Emerging infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Jessica Justman
Timothy Skalland
Ayana Moore
Christopher I Amos
Mark A Marzinke
Sahar Z Zangeneh
Colleen F Kelley
Rebecca Singer
Stockton Mayer
Yael Hirsch-Moverman
Susanne Doblecki-Lewis
David Metzger
Elizabeth Barranco
Ken Ho
Ernesto T A Marques
Margaret Powers-Fletcher
Patricia J Kissinger
Jason E Farley
Carrie Knowlton
Magdalena E Sobieszczyk
Shobha Swaminathan
Domonique Reed
Jean De Dieu Tapsoba
Lynda Emel
Ian Bell
Krista Yuhas
Leah Schrumpf
Laura Mkumba
Jontraye Davis
Jonathan Lucas
Estelle Piwowar-Manning
Shahnaz Ahmed
CoVPN 5002 COMPASS Study Team

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials UnitUM1AI069419 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROY M. GULICK · 2012 to 2026
$44.6M
Columbia Collaborative HIV/AIDS Clinical Trials UnitU01AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HAMMER, SCOTT M · 2007 to 2011
$15.4M
ICAP Clinical Trials UnitUM1AI154468 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WAFAA M. EL-SADR, JESSICA E. JUSTMAN · 2021 to 2026
$13.0M
Global HIV Implementation Science Research Training Grant RenewalT32AI114398 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Yael R Hirsch-Moverman · 2014 to 2026
$4.1M
NIAID NIH HHS T32 AI114398NIAID NIH HHS U01 AI069470NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069419NIAID NIH HHS UM1 AI069470NIAID NIH HHS UM1 AI154468
6 · The paper itself

Abstract

During January-August 2021, the Community Prevalence of SARS-CoV-2 Study used time/location sampling to recruit a cross-sectional, population-based cohort to estimate SARS-CoV-2 seroprevalence and nasal swab sample PCR positivity across 15 US communities. Survey-weighted estimates of SARS-CoV-2 infection and vaccine willingness among participants at each site were compared within demographic groups by using linear regression models with inverse variance weighting. Among 22,284 persons >2 months of age and older, median prevalence of infection (prior, active, or both) was 12.9% across sites and similar across age groups. Within each site, average prevalence of infection was 3 percentage points higher for Black than White persons and average vaccine willingness was 10 percentage points lower for Black than White persons and 7 percentage points lower for Black persons than for persons in other racial groups. The higher prevalence of SARS-CoV-2 infection among groups with lower vaccine willingness highlights the disparate effect of COVID-19 and its complications.

Indexed as

COVID-19VaccinesAdultChildCross-Sectional StudiesHumansPrevalenceSARS-CoV-2Seroepidemiologic StudiesVaccines2019 novel coronavirus diseasecommunity surveyscoronavirus diseaseCOVID-19epidemiologyrespiratory infectionsSARS-CoV-2severe acute respiratory syndrome coronavirus 2surveys and questionnairestime/location samplingUnited Statesviruseszoonoses

Identifiers

PMID38270128
PMCPMC10826749
OpenAlexW4390831165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.